Filing Flows › Comparisons › DWTX vs YARW
Dogwood Therapeutics vs Yarrow Bioscience: DWTX and YARW compared
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $97K for Yarrow Bioscience (Q2 2026).
Where the money goes: DWTX and YARW
Dogwood Therapeutics (DWTX) · Q3 2026
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Yarrow Bioscience (YARW) · Q2 2026
Yarrow Bioscience, Q2 2026: revenue $97K (+41% year over year), net loss $3.0M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Dogwood Therapeutics (DWTX) | Yarrow Bioscience (YARW) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $100K | $97K |
| Revenue growth, Y/Y | — | +41% |
| Operating margin | n/m | n/m |
| Net earnings | −$4.9M | −$3.0M |
| Operating cash flow | −$4.6M | −$2.0M |
Questions
Which is bigger, Dogwood Therapeutics or Yarrow Bioscience?
Dogwood Therapeutics is the larger company: $100K of revenue in its latest quarter (Q3 2026) against $97K for Yarrow Bioscience (Q2 2026).
More: Dogwood Therapeutics earnings · how Dogwood Therapeutics makes money · Yarrow Bioscience earnings · how Yarrow Bioscience makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.